NervGen Pharma Corp. Common stock

NGEN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.37

-$0.07 (-4.86%)

At close: Oct 30, 2026, 4:00 PM ET

$1.55

+$0.18 (+13.14%)

Pre-market: Nov 2, 2026, 4:01 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-4.86%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

24.5

+2.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #934/1028 (Top 91%)

Full Analysis

Key Statistics

Market Data

Market Cap $147.31M

1D Range

1.35 1.50

52W Range

1.35 5.97

Valuation (TTM)

PE -2.23

PB 12.08

EV/EBITDA -10.52

Valuation (NTM)

Forward PE N/A

Forward PEG -0.02

Price Target $12.00

Cash Flow

FCF Yield -14.4%

SBC Adj. FCF Yield -17.0%

SBC Impact -18.2%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -45.0% | -21.7%

FCF 3Y | 5Y -45.1% | -19.4%

Returns

ROA -74.8%

ROE -1156.1%

ROIC -219.9%

Financial Health

Net Cash

C$86.93M ($61.24M)

Current Ratio 1.23

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and...

Sector Healthcare

Industry Biotechnology

Employees 8

IPO Date Feb 8, 2021

Website www.nervgen.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$12.00

Upside

+775.91%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞